**Pralsetinib** ARROW



Presidentinib ARROW  Presidentinib ARROW  SCORE  CURATIVE  Overall Survival / Disease-Free Survival / Pathological Complete Response  NON-CURATIVE  NON-CURATIVE  Overall Survival  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Overall Survival / Disease-Free Survival / Pathological Complete Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  Overall Survival / Disease-Free Survival / Pathological Complete Response	Declarativity ADDOM	Puels stirile APPOW
CURATIVE  Overall Survival / Disease-Free Survival / Pathological Complete Response  NON-CURATIVE  NON-CURATIVE  Overall Survival  Overall Survival  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Serious and disabling adverse effects  Overall Survival  Overall Survival / Disease-Free Survival  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Overall Survival / Disease-Free Survival / Pathological Complete Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  Overall Survival / Disease-Free Survival / Pathological Complete Response	Praisetinid ARROW	Praisetinib ARROW
Overall Survival / Disease-Free Survival / Pathological Complete Response  NON-CURATIVE  NON-CURATIVE  Overall Survival  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Overall Survival  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Overall Survival / Disease-Free Survival / Pathological Complete Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  Overall Survival / Disease-Free Survival / Pathological Complete Response	PRELIMINARY SCORE	SCORE
NON-CURATIVE  ADJUSTMENTS  Quality of life  Progression-Free Survival  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Overall Survival / Disease-Free Survival / Pathological Complete Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  INFORMATION  Tumour type: Endocrine Tumours Therapeutic Indication: Adult and paediatric patients 12 years of age and older with advanced or metastatic RETfusion-positive thyroid cancer who require systemic	CURATIVE	CURATIVE
NON-CURATIVE  ADJUSTMENTS  Quality of life  Progression-Free Survival  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Overall Survival / Disease-Free Survival / Pathological Complete Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  INFORMATION  Turnour type: Endocrine Turnours Therapeutic Indication: Adult and paediatric patients 12 years of age and older with advanced or metastatic RETfusion-positive thyroid cancer who require systemic		
ADJUSTMENTS  Overall Survival  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Serious and disabling adverse effects  Overall Response Rate / Duration of Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  INFORMATION  Tumour type: Endocrine Tumours Therapeutic Indication: Adult and paediatric patients 12 years of age and older with advanced or metastatic RETfusion-positive thyroid cancer who require systemic		Overall Survival / Disease-Free Survival / Pathological Complete Response
ADJUSTMENTS  Overall Survival  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Serious and disabling adverse effects  Overall Response Rate / Duration of Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  INFORMATION  Tumour type: Endocrine Tumours Therapeutic Indication: Adult and paediatric patients 12 years of age and older with advanced or metastatic RETfusion-positive thyroid cancer who require systemic	NON-CURATIVE	
ADJUSTMENTS  Quality of life  Progression-Free Survival  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Serious and disabling adverse effects  Overall Survival  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Overall Response Rate / Duration of Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  INFORMATION  Tumour type: Endocrine Tumours Therapeutic Indication: Adult and paediatric patients 12 years of age and older with advanced or metastatic RefTfusion-positive thyroid cancer who require systemic		NON-CURATIVE
ADJUSTMENTS  Quality of life  Progression-Free Survival  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Serious and disabling adverse effects  Overall Response Rate / Duration of Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  INFORMATION  Turmour type: Endocrine Turmours Therapeutic Indication: Adult and paediatric patients 12 years of age and older with advanced or metastatic RETfusion-positive thyroid cancer who require systemic	ORR	
Progression-Free Survival  Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Serious and disabling adverse effects  Overall Response Rate / Duration of Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  INFORMATION  Tumour type: Endocrine Tumours Therapeutic Indication: Adult and paediatric patients 12 years of age and older with advanced or metastatic RETfusion-positive thyroid cancer who require systemic	ADJUSTMENTS	Overall Survival
Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate  Serious and disabling adverse effects  Overall Response Rate / Duration of Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  INFORMATION  Tumour type: Endocrine Tumours Therapeutic Indication: Adult and paediatric patients 12 years of age and older with advanced or metastatic RETfusion-positive thyroid cancer who require systemic	Quality of life	
Serious and disabling adverse effects  Overall Response Rate / Duration of Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  INFORMATION  Tumour type: Endocrine Tumours Therapeutic Indication: Adult and paediatric patients 12 years of age and older with advanced or metastatic RETfusion-positive thyroid cancer who require systemic		Progression-Free Survival
Serious and disabling adverse effects  Overall Response Rate / Duration of Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  INFORMATION  Tumour type: Endocrine Tumours Therapeutic Indication: Adult and paediatric patients 12 years of age and older with advanced or metastatic RETfusion-positive thyroid cancer who require systemic		
Overall Response Rate / Duration of Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  INFORMATION  Tumour type: Endocrine Tumours Therapeutic Indication: Adult and paediatric patients 12 years of age and older with advanced or metastatic RETfusion-positive thyroid cancer who require systemic		Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate
Overall Response Rate / Duration of Response  Overall Survival / Disease-Free Survival / Pathological Complete Response  INFORMATION  Tumour type: Endocrine Tumours Therapeutic Indication: Adult and paediatric patients 12 years of age and older with advanced or metastatic RETfusion-positive thyroid cancer who require systemic	Serious and disabling adverse effects	
Overall Survival / Disease-Free Survival / Pathological Complete Response  INFORMATION  Tumour type: Endocrine Tumours Therapeutic Indication: Adult and paediatric patients 12 years of age and older with advanced or metastatic RETfusion-positive thyroid cancer who require systemic		
Other adjustments  INFORMATION  Tumour type: Endocrine Tumours Therapeutic Indication: Adult and paediatric patients 12 years of age and older with advanced or metastatic RETfusion-positive thyroid cancer who require systemic		Overall Response Rate / Duration of Response
Tumour type: Endocrine Tumours Therapeutic Indication: Adult and paediatric patients 12 years of age and older with advanced or metastatic RETfusion-positive thyroid cancer who require systemic		Overall Survival / Disease-Free Survival / Pathological Complete Response
Therapeutic Indication: Adult and paediatric patients 12 years of age and older with advanced or metastatic RETfusion-positive thyroid cancer who require systemic	Other adjustments	INFORMATION
Experimental Arm: Pralsetinib Control Arm: Single arm		Therapeutic Indication: Adult and paediatric patients 12 years of age and older with advanced or metastatic RETfusion-positive thyroid cancer who require systemic therapy and who are RAI-refractory Experimental Arm: Pralsetinib

